000178838 001__ 178838
000178838 005__ 20240229143557.0
000178838 0247_ $$2doi$$a10.1016/bs.mcb.2021.07.001
000178838 0247_ $$2pmid$$apmid:35152998
000178838 0247_ $$2ISSN$$a0091-679x
000178838 0247_ $$2ISSN$$a0091-679X
000178838 0247_ $$2doi$$aDOI: 10.1016/bs.mcb.2021.07.001 
000178838 0247_ $$2doi$$aDOI: 10.1016/bs.mcb.2021.07.001
000178838 037__ $$aDKFZ-2022-00301
000178838 041__ $$aEnglish
000178838 082__ $$a570
000178838 1001_ $$0P:(DE-He78)081f0df0551762b7dbb2faabe23023b5$$aPoorebrahim, Mansour$$b0$$eFirst author$$udkfz
000178838 245__ $$aGeneration of CAR-T cells using lentiviral vectors.
000178838 260__ $$aNew York, NY [u.a.]$$bElsevier$$c2022
000178838 3367_ $$2DRIVER$$aarticle
000178838 3367_ $$2DataCite$$aOutput Types/Journal article
000178838 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1646913196_14513
000178838 3367_ $$2BibTeX$$aARTICLE
000178838 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000178838 3367_ $$00$$2EndNote$$aJournal Article
000178838 500__ $$a#EA:D122#LA:D122#
000178838 520__ $$aCancer immunotherapy is nowadays largely focused on the development of therapeutic antibodies and chimeric antigen receptors (CARs). Two CARs targeting CD19 have been approved recently for the treatment of some hematological malignancies. This demonstrates the capability of engineered CAR T cells in generating effective tumor responses. Furthermore, several hundred ongoing clinical trials are exploring the feasibility of CAR-based approaches to target tumor-associated antigens in solid tumors. However, there still remain significant challenges and limitations in the design and production of CAR-modified T cells that need to be addressed, such as more effective transduction methods, expression and exhaustion issues, reliable in vitro and in vivo characterization methods, etc. Here we describe current techniques for generating CAR T cells using lentiviral vectors as well as detailed protocols for their functional characterization.
000178838 536__ $$0G:(DE-HGF)POF4-314$$a314 - Immunologie und Krebs (POF4-314)$$cPOF4-314$$fPOF IV$$x0
000178838 588__ $$aDataset connected to CrossRef Book Series, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
000178838 650_7 $$2Other$$aCAR-T
000178838 650_7 $$2Other$$aCell avidity analysis
000178838 650_7 $$2Other$$aChimeric antigen receptor (CAR)
000178838 650_7 $$2Other$$aElectroporation
000178838 650_7 $$2Other$$aJurkat
000178838 650_7 $$2Other$$aLentiviral vector
000178838 650_7 $$2Other$$aPBMC
000178838 650_7 $$2Other$$aTransposon system
000178838 7001_ $$0P:(DE-HGF)0$$aQuiros-Fernandez, Isaac$$b1
000178838 7001_ $$0P:(DE-He78)148613c9c06b4ac0e307b6fa7787fc9d$$aFakhr, Elham$$b2$$udkfz
000178838 7001_ $$0P:(DE-He78)a30064f6b2d9ab959d35315d7668c091$$aCid-Arregui, Angel$$b3$$eLast author$$udkfz
000178838 773__ $$0PERI:(DE-600)2257731-2$$a10.1016/bs.mcb.2021.07.001$$p39-69$$tMethods in cell biology$$v167$$x0091-679x$$y2022
000178838 909CO $$ooai:inrepo02.dkfz.de:178838$$pVDB
000178838 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)081f0df0551762b7dbb2faabe23023b5$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000178838 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000178838 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)148613c9c06b4ac0e307b6fa7787fc9d$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000178838 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a30064f6b2d9ab959d35315d7668c091$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000178838 9131_ $$0G:(DE-HGF)POF4-314$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImmunologie und Krebs$$x0
000178838 9141_ $$y2022
000178838 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bMETHOD CELL BIOL : 2019$$d2021-05-04
000178838 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2021-05-04
000178838 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2021-05-04
000178838 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2021-05-04
000178838 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-05-04
000178838 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2021-05-04
000178838 915__ $$0StatID:(DE-HGF)1120$$2StatID$$aDBCoverage$$bBIOSIS Reviews Reports And Meetings$$d2021-05-04
000178838 915__ $$0StatID:(DE-HGF)1040$$2StatID$$aDBCoverage$$bZoological Record$$d2021-05-04
000178838 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-05-04
000178838 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2021-05-04
000178838 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2021-05-04
000178838 9202_ $$0I:(DE-He78)D122-20160331$$kD122$$lD122 AG Gezielte Tumorvakzine$$x0
000178838 9201_ $$0I:(DE-He78)D122-20160331$$kD122$$lD122 AG Gezielte Tumorvakzine$$x0
000178838 9200_ $$0I:(DE-He78)D122-20160331$$kD122$$lD122 AG Gezielte Tumorvakzine$$x0
000178838 980__ $$ajournal
000178838 980__ $$aVDB
000178838 980__ $$aI:(DE-He78)D122-20160331
000178838 980__ $$aUNRESTRICTED